Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888189 | 0.88 | NTRK1 (0.40) | JAK2NTRK1CNR2TYK2MAPT | |
| SCHEMBL1668320 | 0.84 | IRAK4 (0.36) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL6888181 | 0.83 | SIRT6 (0.46) | JAK2NTRK1MAPTLMNACYP1A2 | |
| SCHEMBL11922337 | 0.81 | IRAK4 (0.32) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL1667639 | 0.80 | SIRT6 (0.42) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL1668212 | 0.80 | SMN1; SMN2 (0.40) | MAPTCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL1669686 | 0.79 | MAPT (0.42) | MAPTLMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11905053 | 0.74 | KCNH2 (0.38) | JAK2NTRK1CNR2TYK2MAPT | |
| SCHEMBL6888100 | 0.73 | KCNH2 (0.39) | JAK2NTRK1CNR2TYK2MAPT | |
| SCHEMBL6887913 | 0.69 | SIRT6 (0.49) | MAPTL3MBTL1SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488520-B1 | CONDENSED AZINE-DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (NL) | 2015-09-02 | — | — | EP | disclosed |
| EP-2488520-B1 | CONDENSED AZINE-DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (NL) | 2015-09-02 | — | — | EP | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2488520-A1 | CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | MSD Oss B.V. (NL) | 2012-08-22 | — | — | EP | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| WO-2011045258-A1 | CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | N.V. ORGANON (NL) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045258-A1 | CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | N.V. ORGANON (NL) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | CHRNA5, CHRM5, CHRNA7 | JAK2 2088/4885NTRK1 1223/4885CNR2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.